Cantor Fitzgerald Reiterates “Neutral” Rating for Stryker (SYK)

Stryker (NYSE:SYK)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Friday. They currently have a $163.00 price target on the medical technology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 1.61% from the company’s current price.

The analysts wrote, “Announced preliminary FY17 revenue of $3.5B, beating FactSet consensus of $3.4B.””

A number of other research analysts have also recently commented on SYK. Royal Bank of Canada reaffirmed a “buy” rating and set a $155.00 price target on shares of Stryker in a research report on Monday, October 2nd. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Monday, October 2nd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $174.00 price target (up previously from $166.00) on shares of Stryker in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Oppenheimer set a $156.00 price target on Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Finally, Barclays upped their price target on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $155.10.

Shares of Stryker (NYSE:SYK) traded down $2.84 during trading hours on Friday, reaching $160.42. The company’s stock had a trading volume of 650,077 shares, compared to its average volume of 1,104,940. The company has a market cap of $61,100.00, a P/E ratio of 34.20, a PEG ratio of 2.30 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. Stryker has a 52-week low of $117.64 and a 52-week high of $163.74.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $1.39 EPS. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. sell-side analysts forecast that Stryker will post 6.47 EPS for the current year.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. Atlantic Trust Group LLC raised its holdings in shares of Stryker by 1.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 1,186,100 shares of the medical technology company’s stock valued at $168,449,000 after acquiring an additional 13,657 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Stryker by 7.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 739,287 shares of the medical technology company’s stock valued at $104,994,000 after acquiring an additional 50,324 shares in the last quarter. AXA raised its holdings in shares of Stryker by 6.5% in the 3rd quarter. AXA now owns 516,156 shares of the medical technology company’s stock valued at $73,304,000 after acquiring an additional 31,375 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at about $538,000. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Stryker by 0.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 241,591 shares of the medical technology company’s stock valued at $34,311,000 after acquiring an additional 833 shares in the last quarter. 74.90% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at [[permalink]].

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Be the first to comment on "Cantor Fitzgerald Reiterates “Neutral” Rating for Stryker (SYK)"

Leave a comment

Your email address will not be published.


*